凤凰网《风暴眼》出品 作者｜吕银玲 没有电视剧《风吹半夏》中女企业家许半夏绝处逢生的喜极而泣，和想象中不同，当5月13日，义乌外贸老板宋英坤接连收到几位美国客户的消息，通知重 启订单时，他来不及多作感慨，只是迅速对接工厂，安排起工期。 这200万美金的订单，已经停滞了一个月。有的此前只做了一半，就存放在仓库里；有的运到宁波港后，却被要求拖回。算上卸货费、仓储费等，一个柜子 就要损失2万元。此后，它们和外贸商一样，惶惶等待命运的安排。 宁波港 图片来源于网络 直到中美经贸高层在瑞士日内瓦谈判结果传来，美方取消了共计91%的加征关税，暂停实施24%的"对等关税"。持续40天，这场贸易摩擦迷雾终于散去了 一些。 从事外贸行业二十年来，宋英坤总是尽可能保持沉稳冷静，即使在最慌张的时期，他的微信签名也依然体面："Stay easy! Stay calm"。 过去的40天，更像是一场压力测试，疾风过境，百草偃伏，"扛过去"——他心里只有一个声音。 这场关税危机以远超预期的速度成为了历史，回头看去，全球供应链在特朗普政治操弄下显得脆弱不堪。但特朗普还是小看了"世界超市"，如今的宋英 坤，像是刚参加了一场战役的一线冲锋兵，甚 ...

时尚的尽头是极简，穿搭的尽头是白T！ 一件高品质纯色T恤， 外穿搭外套都OK， 随便搭配都是撑子的利器 ，很有高级质感！ 但真正夏天来临时，真心不建议穿纯棉T恤！ 夏季应该都有这样的经历， 棉T恤出汗多了 会 紧紧贴在身上，不仅湿哒哒的，还 有 一股子酸 臭味~ 这些不适感都是因为普通 棉天然特性就是聚热保暖 ，所以冬天要穿棉衣，盖棉被。 棉纤维内部是中空结构， 遇水后会迅速吸湿膨胀 ，从而把透气孔道堵住，就像塞满水的吸管， 水分进入后很难蒸发出来。 如 果 你 是 怕 热 易 汗 体 质 ， 或 者 喜 欢 户 外 运 动 ， 不 妨 试 试 这 款 【培 蒙 黑 科 技 液 氨 冰 感 丝 光 棉 T 恤】 。 同 样 是 T 恤 ， 它 的 体 验 感 会 完 全 不 同 ， 因 为 培 蒙 采 用 了 业 界 领 先 的 双 重 黑 科 技 —— 液 氨 + 丝 光 棉！ 黑科技1—NH3液氨棉处理： 液氨被誉为"冷冻剂 "， 在气化后能吸收大量的热同时还具有一定的不易生菌属性。 不出汗还好，只要一出汗， 纯棉T恤的透气性＝0 ，还容易滋生细菌！ 所以高气温下穿纯棉T恤只能穿个版型. . . . . ...

Core Viewpoint - The article discusses the challenges faced by Mirxes Holding Company Limited (referred to as "Mirxes Group") in commercializing its blood-based cancer screening product GASTROClear, highlighting issues related to technology maturity, market education, and financial sustainability [3][4][24]. Group 1: Product Technology and Market Challenges - Mirxes Group's core technology is based on the detection of microRNA (miRNA), which plays a crucial role in gene regulation and is linked to various diseases, including cancer [5]. - GASTROClear, designed for early gastric cancer screening, claims a sensitivity of 87.5% for stage I gastric cancer, requiring only 5ml of blood for testing [5][6]. - Despite the promising technology, GASTROClear has not yet been commercialized in China, leading to a 16.14% decline in revenue to $2.028 million and a 32.55% increase in losses to $92.2147 million in 2024 [6][24]. Group 2: Pricing and Market Acceptance - GASTROClear is priced between $150 and $250, which is higher than traditional gastroscopy priced at $80 to $200, raising concerns about its competitiveness in the market [8]. - The specificity of GASTROClear is only 68.4%, meaning a significant number of false positives could lead to consumer skepticism and reluctance to adopt the product [9][10]. Group 3: Financial Needs and Investment Landscape - The company has relied heavily on external funding, with significant investments from various entities, including a $87 million C round financing in 2021 [15][16]. - As of March 31, 2025, Mirxes Group had only $2.6125 million in cash and cash equivalents, indicating a pressing need for capital to sustain operations [18]. - The company has not demonstrated the ability to generate revenue independently, with R&D expenses accounting for 94.19% of revenue in 2024, leading to a cumulative loss of $218 million since 2022 [20][23]. Group 4: Regulatory and Market Entry Barriers - Even if GASTROClear receives regulatory approval, the lack of a comprehensive cancer screening system in China poses significant challenges for market penetration [22]. - The Chinese healthcare system is primarily government-driven, and without support from public insurance, widespread adoption of cancer screening products like GASTROClear is unlikely [22].

据彭博社5月20日报道，美国政府贸易委员会周二得出结论，从东南亚进口太阳能产品威胁到国内制造 商。这意味着对当地四个国家的相关设备征收高关税已成定局。 该国国际贸易委员会当天表决认定，从柬埔寨、马来西亚、泰国和越南进口的太阳能电池和组件正损害 美国制造商利益。由此相关关税跨过了全面生效的最终关键门槛，为6月开征奠定了基础。 根据美国商务部上个月实际算出的关税，柬埔寨部分制造商面临的税率将高达3521%，反映出该国决定 停止配合美国调查的影响。其它国家和企业的税率要低得多。越南平均税率在396%，泰国为375%，马 来西亚则是34%。 美国此前进行了长达一年的贸易调查，认为上述四国的太阳能产品制造商不公平地受益于政府补贴，并 且以低于生产成本的价格向美国出口。调查应美国太阳能制造商的要求进行，并在美国前总统乔·拜登 任内启动。 【 热门视频推荐 】 由凤凰网主办的"2025中国企业出海高峰论坛"将于6月28-29日在深圳举行。论坛以"更开放的世界 更共 赢的机遇"为主题，探讨新兴市场出海攻略，汇聚30余国经贸代表、超50家行业领军企业及百余位政策 制定者，聚焦政策研判、产业实战与区域合作，为中国企业全球化提供系 ...

Core Viewpoint - The article discusses the recent challenges faced by Bona Film Group, highlighting issues related to financial misconduct, market performance, and the company's declining position in the Chinese film industry [2][10][30]. Group 1: Financial Misconduct and Regulatory Actions - Bona Film Group's chairman Yu Dong and vice president Qi Zhi were found to have violated regulations by misusing non-operating funds exceeding 200 million yuan and 260 million yuan in 2022 and 2023 respectively [10][11]. - The Xinjiang Securities Regulatory Bureau has imposed corrective measures on Bona and issued warning letters to Yu Dong and Qi Zhi, which will be recorded in the capital market integrity archives [7][10]. - Following the announcement, Bona's stock price fell to 4.41 yuan per share as of May 9 [8]. Group 2: Recent Market Performance and Challenges - The film "Operation Dragon" faced significant setbacks, including a poor reception and eventual withdrawal from the Spring Festival release, leading to a box office return of only 350 million yuan against a production cost of 1 billion yuan [16][36]. - Bona's market position has deteriorated, with its market value at 6.062 billion yuan, significantly lower than competitors like Wanda Film at 22.512 billion yuan and Light Media at 54.594 billion yuan [36]. - The company reported a net loss of 237 million yuan in 2023 and a cumulative loss of 356 million yuan in the first three quarters of 2024 [39][42]. Group 3: Historical Context and Business Model - Founded in 2003, Bona Film Group was the first private company to obtain a film distribution license in China, growing alongside the Chinese film market [25][29]. - The company has historically relied on a successful model of producing patriotic films, which initially provided a competitive edge but has shown signs of fatigue in the current market environment [30][36]. - Bona's financial struggles are compounded by a significant drop in shareholder confidence, with major institutional investors reducing their stakes from 16.6% to 9.2% [42].

Core Viewpoint - The article discusses a significant increase in the number of A-share companies announcing the termination of major shareholder agreement transfers, indicating a potential restructuring of traditional transaction methods in the market [2][3]. Group 1: Termination of Agreement Transfers - Since May, 12 A-share companies have announced the termination of major shareholder agreement transfers, which is equivalent to the total number of such cases in the first four months of the year, accounting for nearly one-fourth of all such cases in 2023 [2]. - Approximately 250 listed companies disclosed major shareholders and executives' agreement transfer reduction plans in the past year, showing a slight increase compared to the previous 12 months, indicating that agreement transfers are still being allowed in a relatively inactive stock market [3]. - The recent terminations predominantly involve controlling shareholders or actual controllers, often due to restrictions on secondary market reductions caused by the company's poor performance, such as being below net asset value or failing to meet dividend standards [4]. Group 2: Challenges in Identifying Relationships - The complexity of identifying "invisible relationships" in agreement transfers poses challenges, as companies often claim ignorance about the specifics of the shareholders' actions [5]. - The recent cases of terminated agreements reveal common characteristics, such as the transferors being actual controllers or related parties, and the transferees often being private equity funds or individuals with limited disclosed backgrounds [8]. Group 3: Buyer Financial Viability - The financial strength and sources of funds for some buyers in agreement transfers are often unclear, raising concerns about their ability to fulfill payment obligations [12][13]. - For instance, a terminated agreement involving Tian Neng Heavy Industry indicated that the transfer was contingent on the successful fundraising of a trust plan, which had not been achieved, leading to the termination of the agreement [12]. Group 4: Restrictions on Shareholder Reductions - Controlling shareholders facing restrictions on reductions due to poor performance are increasingly using agreement transfers as a workaround to liquidate their holdings [16]. - The case of Kosen Technology illustrates how controlling shareholders can bypass reduction restrictions through agreement transfers, leading to significant short-term stock price increases driven by market speculation [16][17]. Group 5: Regulatory and Transparency Issues - The article highlights the need for increased transparency in agreement transfers, as they may involve complex arrangements that include asset restructuring and undisclosed agreements [23][24]. - Experts suggest that regulatory bodies should enhance scrutiny of these transactions to prevent potential abuses and ensure that the interests of public investors are protected [24][25].

Market Overview - The major U.S. stock indices collectively declined, with the Dow Jones down 0.27%, Nasdaq down 0.38%, and S&P 500 down 0.39% [1] - Large tech stocks mostly fell, with Amazon and Google dropping over 1% [2] Chinese Stocks - The Nasdaq Golden Dragon China Index fell by 0.65%, with Ctrip down over 5%, NIO down nearly 2%, and iQIYI and Xpeng down over 1%, while Alibaba rose over 1% [3] Precious Metals - The precious metals sector saw significant gains, with Vista Gold up over 16%, Coeur Mining up over 5%, Harmony Gold up over 4%, and Pan American Silver up over 3% [3] Tesla and Political Contributions - Elon Musk announced he would "significantly reduce" future political spending, which could impact Trump's fundraising efforts for the 2026 midterm elections [3] - Musk was the largest single donor in U.S. election history, contributing approximately $250 million during the last presidential election, primarily supporting Trump [4] Tesla Stock Performance - Following Musk's announcement, Tesla's stock initially rose nearly 4% before closing at $343.82, a gain of 0.51%, with a market capitalization of $1.11 trillion [5] - Tesla's stock price has experienced volatility since Trump's election, with a 50% increase shortly after, followed by a 40% decline due to controversies surrounding Musk's government role [7][8] Tax Reform Stalemate - Trump's tax reform proposal is facing challenges, particularly from Republican lawmakers from high-tax states who are resisting changes to the state and local tax (SALT) deduction cap [9][10] - The proposed increase of the SALT deduction cap from $10,000 to $30,000 has not satisfied some Republican members, leading to a potential deadlock in passing the legislation [10][11]

持续近两个月的胖都来撞名胖东来事件，终于告一段落。 5月20日，多位网友发布视频称，胖都来商场已将名字改为"盈都来"。网络视频显示，在商场外墙 上，红色的"胖都来"三个字已改为白色的"盈都来"。 图源/正在新闻截图 5月10日晚间，都建明表示，"胖都来"名字可以换，同时也向网友表示，"你们觉得换哪个好，给我 提提建议。"他表示，名字不重要，重要的是能否帮服装厂清库存、帮年轻人低成本创业。 据胖都来官方微信公众号，其标识已改为盈都来。目前，该公众号尚未有内容发布。此外，胖都来 的法定代表人都建明的抖音号，也从胖都来改为盈都来。 据21世纪经济报道，今年3月底，浙江海宁即将开业的商场"胖都来"因撞名"胖东来"，引发网友热 议。对此，胖东来工作人员回应称， "胖都来"取名有蹭热度的嫌疑，会进行法务评估 。 5月1日，"胖都来"商场高调开业，多位明星艺人送上祝福，再次陷入舆论风波。 对于名称引发的争议，胖都来官方在其社交账号回应称，"胖"寓意丰盈、富足、美好，这一理念贯 穿于公司的经营中，确保商品琳琅满目、价格实惠、服务贴心；"都"字取自集团董事长都建明的姓 氏。 关于"胖都来"撞名，胖东来回应称，已经取证并向市场监 ...

Core Viewpoint - Yuyue Medical has faced significant challenges post-pandemic, with a notable decline in revenue and profit, raising concerns about its future growth and market position [2][6]. Group 1: Performance Decline - In 2020, Yuyue Medical's revenue surged by 45.08% to 6.726 billion yuan, and net profit exceeded 1 billion yuan for the first time, reaching 1.759 billion yuan [2]. - However, the company has struggled to maintain growth, with a revenue decline of 5.09% in 2024 to 7.566 billion yuan and a net profit drop of 24.63% to 1.806 billion yuan, marking the first dual decline since its IPO [2][4]. - As of May 16, 2025, the company's market capitalization was 35.8 billion yuan, only about one-third of its ambitious target [2]. Group 2: Business Segmentation and Revenue Sources - Yuyue Medical's business is primarily focused on home medical devices and clinical products, with key segments including respiratory therapy, blood glucose management, and home health testing [3]. - The company restructured its business segments into five categories, but only the respiratory therapy segment has shown consistent revenue growth, while others have stagnated since 2020 [4]. - In 2024, the respiratory therapy segment saw a significant revenue decline of 22.42%, while home health testing remained relatively stable with a slight decrease [4]. Group 3: M&A Strategy and Goodwill Concerns - Yuyue Medical has relied on mergers and acquisitions (M&A) to expand its business and product offerings, acquiring several companies since 2015 [5]. - Despite these efforts, the performance of some acquired entities has been underwhelming, leading to a goodwill of 1.084 billion yuan as of the end of 2024, raising concerns about potential impairment risks [6]. Group 4: Marketing vs. R&D Investment - The company has prioritized marketing over research and development (R&D), with sales expenses exceeding 1 billion yuan annually, reaching a peak of 1.361 billion yuan in 2024, while R&D expenses were only 547 million yuan [7]. - Despite increasing R&D investment since 2018, product quality issues have been reported, affecting consumer trust and brand reputation [7][8]. Group 5: Online Sales and Brand Image - Yuyue Medical has expanded its online sales channels, leading to increased sales costs, particularly in e-commerce platform fees, which rose by 43.44% in 2024 [8]. - Negative publicity regarding product quality and pricing practices has damaged the company's brand image, potentially impacting long-term online sales growth [8]. Group 6: International Expansion and Profitability Challenges - The company is also focusing on international markets, with overseas revenue accounting for 12.54% in 2024 [8]. - Despite a 9.17% increase in revenue in the first quarter of 2024, net profit declined, indicating challenges in achieving sustainable profitability [8].

Core Viewpoint - The article discusses the rise, fall, and potential resurgence of the Jiangxi-based bottled water brand "Runtian," highlighting its challenges in a competitive market and its recent move to go public through a reverse merger with ST United [1][2]. Group 1: Historical Context and Market Position - Runtian was founded in 1994 and quickly gained popularity in Jiangxi with its 1 yuan pricing strategy and memorable advertising slogan, achieving a market penetration rate exceeding 50% [2][4]. - By 2000, Runtian expanded into national markets, entering provinces like Hunan and Hubei, and implemented a DRP distribution system [3]. - In 2007, Runtian received a 200 million yuan investment from Softbank SAIF, which helped it scale operations and expand its product line, including the premium "Runtian Cui" mineral water [4][5]. Group 2: Challenges and Crisis - Runtian's IPO plans were derailed due to market conditions, and a significant brand crisis occurred in 2013 when it launched a controversial "special supply" mineral water, leading to a decline in brand value [6][8]. - By 2014, Runtian faced severe financial difficulties, including debt crises and unpaid wages, prompting a restructuring that led to the establishment of Jiangxi Runtian Industrial Co., Ltd. [9][10]. Group 3: Recent Developments and Future Prospects - In 2016, Jiangxi Tourism Group became the controlling shareholder of Runtian, marking its transition to a state-controlled mixed-ownership enterprise [9][10]. - Runtian has been attempting to address issues related to industry competition, particularly with Jiangxi Nanshan Yiquan, which poses a potential conflict of interest due to shared ownership [10][12]. - The company is now pursuing a reverse merger with ST United, which could provide a pathway to public listing and financial recovery, although both companies face significant operational challenges [18][21]. Group 4: Market Dynamics - The bottled water market in China is highly concentrated, with major brands like Nongfu Spring and Wahaha holding over 80% market share, making it difficult for regional brands like Runtian to compete [14][15]. - Runtian's limited geographic footprint and product diversification hinder its ability to expand nationally, as it primarily relies on its water sources in Jiangxi [15][16].